<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037372</url>
  </required_header>
  <id_info>
    <org_study_id>DN2017</org_study_id>
    <nct_id>NCT03037372</nct_id>
  </id_info>
  <brief_title>Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial</brief_title>
  <acronym>STAR</acronym>
  <official_title>Statin Adjunct Therapy Among HAART-treated Adults in Sub-Saharan Africa: Equivalence of Atorvastatin and Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether 36 months of daily atorvastatin or rosuvastatin have
      equivalent effects in reduction of immune activation, inflammation and immune aging, when
      given as adjunct therapy among patients receiving antiretroviral therapy in an African cohort
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label trial
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Similar rate of reduction of immune activation between atorvastatin and rosuvastatin arms (p&lt;o.05)</measure>
    <time_frame>12 months</time_frame>
    <description>measured by percentage of HLADR+CD38+T-cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Similar rate of change of immune aging markers, between ART-treated adults with and without statin (atorvastatin and rosuvastatin) adjunct therapy arms (P-value&lt;0.05)</measure>
    <time_frame>36 months</time_frame>
    <description>Measured by Percentage of CD4+ and CD8+ naive T-cells or percentage of expressing Ki67 T-cells or percentage of low CFSE+T-cells or increase in percentage of CD28-/CD57+ T-cells or percentage of individuals with low host responses to influenza vaccine among HIV-infected adults at ART initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Similar rate of reduction of inflammatory markers, between atorvastatin and rosuvastatin arms (p&lt;0.05)</measure>
    <time_frame>36 months</time_frame>
    <description>Measured by levels of IL6 in pg/ml, hsCRP in pg/ml, d-dimers in pg/ml, IFABP in pg/ml, and LPS in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological pathways affected by atorvastatin and rosuvastatin</measure>
    <time_frame>36 months</time_frame>
    <description>number of genes down-regulated by either atorvastatin or rosuvastatin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>ART-Atorvastatin adjunct therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART, atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART-Rosuvastatin adjunct therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART, rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART-without statin adjunct therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART, no statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy-HIV-negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age-matched HIV-negative, healthy volunteers from the same community</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART, Atorvastatin</intervention_name>
    <description>ART, Atorvastatin</description>
    <arm_group_label>ART-Atorvastatin adjunct therapy</arm_group_label>
    <other_name>Atovastatin adjunct therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART, Rosuvastatin</intervention_name>
    <description>ART, Rosuvastatin</description>
    <arm_group_label>ART-Rosuvastatin adjunct therapy</arm_group_label>
    <other_name>Rosuvastatin adjunct therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART, No statin</intervention_name>
    <description>ART, No statin</description>
    <arm_group_label>ART-without statin adjunct therapy</arm_group_label>
    <other_name>No statin adjunct therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Healthy-HIV-negative</intervention_name>
    <description>Age-matched, Healthy HIV-negative</description>
    <arm_group_label>Healthy-HIV-negative</arm_group_label>
    <other_name>HIV-negative controls</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-positive individuals 18 years and older, that have initiated three first-line drug
             highly active antiretroviral therapy within three months within the Infectious
             Diseases Institute HIV treatment cohort

          -  Individuals that provide written informed consent to participate in the clinical trial

        Exclusion Criteria:

        Individuals with dyslipidemia and eligible to receive or already receiving statin therapy

          -  Pregnant or lactating mothers

          -  Individuals with another active or controlled inflammatory condition

          -  Individuals with deranged liver function tests 3 fold and above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damalie Nakanjako, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University College of Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damalie Nakanjako, PhD</last_name>
    <phone>+256772411273</phone>
    <email>dnakanjako@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rose Nabatanzo, MSC</last_name>
    <phone>+256772603646</phone>
    <email>rosemagala@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, Clagett B, Robinson J, Lederman MM, McComsey GA. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):396-404. doi: 10.1097/QAI.0000000000000478.</citation>
    <PMID>25514794</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, Kaleebu P, Kambugu AD, Kamya MR, Sekaly R, Elliott A, Mayanja-Kizza H. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health. 2015 Mar;20(3):380-90. doi: 10.1111/tmi.12442. Epub 2015 Jan 6.</citation>
    <PMID>25441397</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adults</keyword>
  <keyword>antiretroviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with the Infectious Diseases Institute, according to the IDI data sharing policy</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

